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Background 
The World Health Organization recommends ACTs for 
the treatment of uncomplicated P. falciparum malaria, 
and state that the first-line ACT adopted in a region or 
country should have a treatment failure rate of less than 
10%. Current available combinations are compared. 
Inclusion criteria 
Studies:  
Randomized controlled trials. Last search date. 
Participants: 
Adults and children with a microscopically confirmed 
diagnosis of uncomplicated P. falciparum malaria. 
Intervention: 
A three-day course of: dihydroartemisinin-piperaquine; 
artesunate plus mefloquine; artemether-lumefantrine (six 
doses); artesunate plus amodiaquine; artesunate plus 
sulfadoxine-pyrimethamine or amodiaquine plus 
sulfadoxine-pyrimethamine (a non-artemisinin-based 
combination therapy still in use in some African 
countries). 
Outcomes: 
Treatment failure at days 28, 42, and 63, 
gametocytemia, adverse events, serious adverse events. 
Results 
• Fifty studies were included: 21 with concealed 
allocation, most conducted in Africa (31) and Asia 
(17). Pregnant and lactating women and young infants 
(less than 1 year in Asia and less than 6 months in 
Africa) were excluded from all trials. 
• Dihydroartemisinin-piperaquine, performed well 
compared to the ACTs in common use (vs. mefloquine 
in Asia: PCR adjusted treatment failure day 63 relative 
risk 0.39, 95% confidence interval 0.19 to 0.79; 1062 
participants, 3 trials; versus artemether-lumefantrine in 
Africa: PCR adjusted failure day 42; RR 0.39, 95% CI 
0.24 to 0.64; 1136 participants, 3 trials). It did 
however have a failure rate above 10% in one trial 
from Papua New Guinea. 
• Artemether-lumefantrine and artesunate plus 
amodiaquine both performed well in most studies 
which evaluated them, but failure rates above 10% 
have been reported with both combinations from 
study sites in Uganda. 
• There is very little good quality evidence available 
comparing artesunate plus sulfadoxine-pyrimethamine 
to dihydroartemisinin-piperaquine, artesunate plus 
mefloquine or artemether-lumefantrine but it has 
performed well in head to head trials with artesunate 
plus amodiaquine in Africa. 
• ACTs were superior to amodiaquine plus sulfadoxine-
pyrimethamine in East Africa (PCR adjusted treatment 
failure day 28: artemether-lumefantrine vs AQ+SP; RR 
0.12, 95% CI 0.06 to 0.24; 618 participants, 2 trials; 
artesunate plus amodiaquine vs AQ+SP; RR 0.44, 
95% CI 0.22 to 0.89; 1515 participants, 3 trials). 
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Which artemisinin-based combination therapies (ACTs) are effective for 
treating uncomplicated P. falciparum malaria? 
Generally, all of the WHO recommended artemisinin combination treatments were very 
effective, but trials report true failure rates exceeding 10% in some areas. 
Authors’ conclusions 
Implications for practice:  
In Asia, dihydroartemisinin-piperaquine was at least as effective as artesunate plus mefloquine (HIGH quality 
evidence), providing a valuable alternative to the ACTs in current use. 
In Africa, dihydroartemisinin-piperaquine was at least as effective as artemether-lumefantrine (HIGH quality 
evidence), and artesunate plus amodiaquine (MODERATE quality evidence), and these combinations continue to 
perform well in most areas. Artesunate plus mefloquine is also likely to be an effective option in Africa where 
resistance to mefloquine is rare, although it has been little studied in this context. 
Amodiaquine plus sulfadoxine-pyrimethamine is no longer an effective first-line treatment in several East African 
countries (MODERATE quality evidence). It was, however, still performing well in Senegal in 2003, Madagascar in 
2006, and Burkina Faso in 2005. 
Evidence of the safety of ACTs is accumulating. Serious adverse events with these drugs appear to be rare. 
However, these trials are too small to detect rare but clinically important events and so it is imperative that active 
monitoring continues. 
Implications for research: 
Examples of treatment failure rates above 10% exist for all ACTs. The local efficacy of the first-line ACT should 
therefore continue to be monitored after its introduction to detect resistance. 
Further trials are necessary to assess the efficacy and safety of these combinations in pregnant women and very 
young infants.  
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